@article{80981029ed5f47c88c27cf7e5137d5fd,
title = "The need for broadly protective COVID-19 vaccines: Beyond S-only approaches",
keywords = "B-cell, COVID-19, Coronavirus, HLA class I, HLA class II, Immune response, Peptide, SARS-CoV-2, T-cell, Universal vaccine, Variant",
author = "Poland, {Gregory A.} and Ovsyannikova, {Inna G.} and Kennedy, {Richard B.}",
note = "Funding Information: Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergent Biosolutions, Johnson & Johnson/Janssen Global Services LLC, Dynavax, Genentech, Eli Lilly and Company, Kentucky Bioprocessing, Bavarian Nordic, AstraZeneca, Exelixis, Regeneron, Vyriad, Moderna, and Genevant Sciences, Inc. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. Drs. Poland and Ovsyannikova hold patents related to vaccinia and measles peptide vaccines. Dr. Kennedy holds a patent related to vaccinia peptide vaccines. Drs. Poland, Ovsyannikova, and Kennedy have received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.",
year = "2021",
month = jul,
day = "13",
doi = "10.1016/j.vaccine.2021.06.028",
language = "English (US)",
volume = "39",
pages = "4239--4241",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "31",
}